100 tracked 13F filers disclose a position in PHVS as of the latest SEC 13F filings, a combined $1.4B in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | GENERAL ATLANTIC, L.P. | $226.9M | 8.0M | —Held | Q1 2026 | |
| 2 | FMR LLC | $177.5M | 6.3M | ▼−1.8% Reduced · −115K sh | Q1 2026 | |
| 3 | Foresite Capital Management IV, LLC | $135.0M | 4.8M | —Held | Q1 2026 | |
| 4 | VIKING GLOBAL INVESTORS LP | $103.2M | 3.7M | —Held | Q1 2026 | |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. | $88.3M | 3.1M | —Held | Q1 2026 | |
| 6 | Bain Capital Life Sciences Investors, LLC | $75.6M | 2.7M | ▼−4.5% Reduced · −127K sh | Q1 2026 | |
| 7 | Commodore Capital LP | $54.2M | 1.9M | ▲+1.6% Added · +30K sh | Q1 2026 | |
| 8 | Novo Holdings A/S | $49.4M | 1.8M | —Held | Q1 2026 | |
| 9 | Saturn V Capital Management LP | $33.9M | 1.2M | ▲+5.4% Added · +61K sh | Q1 2026 | |
| 10 | Point72 Asset Management, L.P. | $28.4M | 1.0M | ▲+42% Added · +295K sh | Q1 2026 | |
| 11 | Cormorant Asset Management, LP | $28.3M | 1.0M | ▼−7.7% Reduced · −83K sh | Q1 2026 | |
| 12 | Sofinnova Investments, Inc. | $23.1M | 818K | ▲+9.8% Added · +73K sh | Q1 2026 | |
| 13 | 5AM Venture Management, LLC | $22.5M | 798K | —Held | Q1 2026 | |
| 14 | Polar Capital Holdings Plc | $22.1M | 781K | ▲+228% Added · +543K sh | Q1 2026 | |
| 15 | BlackRock, Inc. | $21.4M | 757K | ▲+6.9% Added · +49K sh | Q1 2026 | |
| 16 | Soleus Capital Management, L.P. | $19.8M | 702K | —Held | Q1 2026 | |
| 17 | Rock Springs Capital Management LP | $18.2M | 646K | ▲+3.5% Added · +22K sh | Q1 2026 | |
| 18 | Kynam Capital Management, LP | $18.1M | 640K | —Held | Q1 2026 | |
| 19 | Patient Square Capital LP | $13.9M | 493K | ▼−9.2% Reduced · −50K sh | Q1 2026 | |
| 20 | Ikarian Capital, LLC | $13.8M | 487K | —Held | Q1 2026 | |
| 21 | BALYASNY ASSET MANAGEMENT L.P. | $13.1M | 462K | ▼−6.8% Reduced · −34K sh | Q1 2026 | |
| 22 | PRICE T ROWE ASSOCIATES INC /MD/ | $12.5M | 442K | ▼−53% Reduced · −499K sh | Q1 2026 | |
| 23 | Eversept Partners, LP | $11.5M | 407K | ▼−7.3% Reduced · −32K sh | Q1 2026 | |
| 24 | BAKER BROS. ADVISORS LP | $10.6M | 375K | —Held | Q1 2026 | |
| 25 | D. E. Shaw & Co., Inc. | $9.1M | 321K | ▲+23% Added · +61K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 7 funds opened a new position in PHVS and 20 added to an existing one, while 22 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| XENON PHARMACEUTICALS INCXENE | 46 funds | $1.3B |
| REVOLUTION MEDICINES INCRVMD | 41 funds | $2.8B |
| COGENT BIOSCIENCES INCCOGT | 41 funds | $1.4B |
| VERA THERAPEUTICS INCVERA | 40 funds | $1.0B |
| AMAZON.COM INCAMZN | 39 funds | $97.0B |
| ELI LILLY & COLLY | 39 funds | $40.3B |
| INTUITIVE SURGICAL INCISRG | 39 funds | $16.0B |
| RHYTHM PHARMACEUTICALS INCRYTM | 39 funds | $1.4B |
| VAXCYTE INCPCVX | 39 funds | $916.9M |
| CYTOKINETICS INCCYTK | 39 funds | $890.1M |
| MICROSOFT CORPMSFT | 38 funds | $137.8B |
| META PLATFORMS INC-CLASS AMETA | 38 funds | $61.6B |
Ranked by how many of PHVS's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jul 13, 2026 | Modig Berndt | Chief Executive Officer, Director | Sell (S) | 2K | $80K |
| Jun 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus | Director | Sell (S) | 31K | $1.1M |
| Jun 30, 2026 | Lesage Anne | Chief Early Development | Sell (S) | 28K | $989K |
| Jun 30, 2026 | Lesage Anne | Chief Early Development | Sell (S) | 31K | $1.1M |
| Jun 29, 2026 | Schikan Johannes Gerardus Christiaan Petrus | Director | Sell (S) | 7K | $241K |
| Jun 29, 2026 | Lesage Anne | Chief Early Development | Sell (S) | 2K | $81K |
| Jun 29, 2026 | Lesage Anne | Chief Early Development | Sell (S) | 8K | $291K |
| Jun 29, 2026 | Lesage Anne | Chief Early Development | Sell (S) | 7K | $245K |
| Jun 29, 2026 | Schikan Johannes Gerardus Christiaan Petrus | Director | Sell (S) | 2K | $84K |
| Jun 26, 2026 | Lu Peng | Chief Medical Officer | Sell (S) | 15K | $500K |
| Jun 25, 2026 | Lu Peng | Chief Medical Officer | Sell (S) | 12K | $400K |
| Jun 25, 2026 | Lu Peng | Chief Medical Officer | Sell (S) | 3K | $119K |
Connected entities for PHVS
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/PHVS/capital-change-brief"
Use Arkolith's capital_change_brief for PHVS. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for PHVS. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.